Annuncio • Jun 01
Selvita S.A., Annual General Meeting, Jun 24, 2026 Selvita S.A., Annual General Meeting, Jun 24, 2026, at 11:30 Central European Standard Time. Reported Earnings • May 26
First quarter 2026 earnings released: zł0.30 loss per share (vs zł0.054 loss in 1Q 2025) First quarter 2026 results: zł0.30 loss per share (further deteriorated from zł0.054 loss in 1Q 2025). Revenue: zł80.0m (down 12% from 1Q 2025). Net loss: zł5.45m (loss widened 453% from 1Q 2025). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance. Annuncio • Nov 15
Selvita S.A. to Report Q3, 2025 Results on Nov 20, 2025 Selvita S.A. announced that they will report Q3, 2025 results on Nov 20, 2025 Annuncio • Aug 21
Selvita S.A. to Report First Half, 2025 Results on Sep 18, 2025 Selvita S.A. announced that they will report first half, 2025 results on Sep 18, 2025 Annuncio • Dec 11
Selvita Strengthens Management Structure in Sales and Drug Development Segment Selvita S.A. announced the hiring of Dr. Paul Overton as Chief Commercial Officer. Bringing over 25 years of expertise in the pharmaceutical, biotechnology and CRO industries, Dr. Overton has an impressive track recording of managing business development at companies such as Sygnature Discovery, Eurofins, Evotec and Aptuit. His career has been defined by driving global sales growth, forging strategic partnerships with biopharmaceutical companies, and steering dynamic, fast-growing organizations to success. Additionally, Dr. Milosz Gruca will assume the role of Global Head of Drug Development, where he will oversee the company's rapidly expanding drug development segment and the area of services dedicated to biologic drugs. The hiring of Dr. Paul Overton as Chief Commercial Officer reflects Selvita's commitment to enhancing its international business development efforts. During his career, he has been personally responsible for achieving sales targets of several hundred million euros per year, and has played instrumental roles in numerous M&A transactions. Dr. Overton specializes in sales development of dynamically growing companies and management of global sales teams. His experience and expertise spans supporting the development of new services, optimizing the operations of sales structures and building strategic partnerships with biopharmaceutical companies. As Chief Commercial Officer, Dr. Overton will be responsible for managing the international business development team and strengthening Selvita's sales activities. His extensive industry experience, international relationships and scientific profile, will support the Group's position and growth in global markets. Reported Earnings • Sep 27
Second quarter 2024 earnings released: zł0.55 loss per share (vs zł0.43 profit in 2Q 2023) Second quarter 2024 results: zł0.55 loss per share (down from zł0.43 profit in 2Q 2023). Revenue: zł80.9m (down 9.2% from 2Q 2023). Net loss: zł10.0m (down 227% from profit in 2Q 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Reported Earnings • May 23
First quarter 2024 earnings released: zł0.12 loss per share (vs zł0.14 profit in 1Q 2023) First quarter 2024 results: zł0.12 loss per share (down from zł0.14 profit in 1Q 2023). Revenue: zł77.2m (down 16% from 1Q 2023). Net loss: zł2.14m (down 182% from profit in 1Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Annuncio • May 08
Selvita S.A. (WSE:SLV) acquired PozLab sp. z o.o from YouNick Mint Sp. z o.o. Selvita S.A. (WSE:SLV) agreed to acquire PozLab sp. z o.o from YouNick Mint Sp. z o.o. for PLN 25 million on March 27, 2024. The consideration PLN 21 million will be paid on the day of acquisition of the Shares and PLN 4 million will be retained by the Issuer for a period of up to 12 months from the date of closing the Transaction as security for any, specifically enumerated in the Agreement, events or claims by third parties against PozLab, as well as to secure settlements related to price adjustments. The acquisition of shares will be financed from the issuer's own funds. The Issuer will consider refinancing the Transaction with debt in the future. Upon the fulfillment of the following conditions: i) obtaining the consent of the National Centre for Research and Development (in Polish: Narodowe Centrum Badan i Rozwoju), granted in at least documentary form, for the acquisition of all Shares by the Issuer; and ii) completion of the capital restructuring process of the Seller's group by concluding, between PozLab and a third party designated by the Seller, an agreement for the sale of 100% of the shares in Applied Manufacturing Science sp. z o.o., a subsidiary of PozLab. The parties may agree on a different closing date. In the event of non-fulfillment of the Suspensive Conditions by September 30, 2024, the Issuer is entitled to withdraw from the Preliminary Agreement. In 2023, PozLab recorded revenues of PLN 15.3 million and estimated EBITDA of PLN 1.7 million. The completion of the transaction is dependent on obtaining consent from the National Centre for Research and Development for the acquisition. The transaction is expected to be closed on 30th business day.
Selvita S.A. (WSE:SLV) completed the acquisition of PozLab sp. z o.o from YouNick Mint Sp. z o.o. on May 7, 2024. Reported Earnings • Mar 31
Full year 2023 earnings released: EPS: zł3.80 (vs zł1.65 in FY 2022) Full year 2023 results: EPS: zł3.80 (up from zł1.65 in FY 2022). Revenue: zł351.9m (down 15% from FY 2022). Net income: zł69.9m (up 131% from FY 2022). Profit margin: 20% (up from 7.3% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Annuncio • Mar 19
Selvita S.A. Launches Biologic Drug Discovery and Development Services Selvita S.A. announced a strategic initiative to significantly expand its services portfolio and enter the field of biologic drug discovery and development, by adding comprehensive therapeutic antibody discovery and development capabilities to its portfolio. The company will employ a highly proficient team of experts specializing in the discovery and development of therapeutic antibodies and rent fully equipped laboratories. As Selvita ventures into the dynamic field of biologic drug discovery, it will offer a suite of fully comprehensive antibody-related services, encompassing a wide spectrum of activities essential for therapeutic antibody discovery. Selvita will open a new research site in Wroclaw, Poland, where it will rent over 400 sq m of laboratories along with all necessary infrastructure. The company has also already secured the equipment required to conduct antibody discovery-related research studies. Selvita plans to initially contract 16 highly experienced scientists, formerly at Pure Biologics, specializing in antibody engineering. The intention of the company is to double the headcount within the next 3 years. Antibody discovery and development form the cornerstone of expansion into a comprehensive suite of services for biologics drug discovery and development. With biologics emerging as the fastest-growing sector within life sciences, recognize the immense potential of this strategic move. the company eagerly anticipate welcoming new colleagues and seamlessly integrating the Wroclaw site into Selvita's operations. Entering into the realm of biological drugs discovery and development not only marks a significant expansion for Selvita, but also paves the way for new markets and opportunities. By venturing into this new field, Selvita is poised to augment its existing portfolio of services in small molecules' discovery and development. The introduction of new services for biologics will also seamlessly complement Selvita's current offerings in the area of production of high-quality recombinant proteins and a comprehensive suite of structural biology services, including the production of recombinant antibodies in various formats, antibody chimerization, engineering of bispecific antibodies, isotype switching, and a range of mAbs-based assays. This strategic expansion enables Selvita to establish a truly comprehensive and competitive offer of "All Under One Roof" Protein Services, addressing the needs and expectations of its current and potential customers, and positioning itself as a partner of choice for companies looking for a high-quality service in this area. With an extensive range of capabilities covering both small molecules and biological drugs, Selvita is primed to meet diverse client needs and seize emerging opportunities in the rapidly evolving biological drugs market. Reported Earnings • Jun 04
First quarter 2023 earnings released First quarter 2023 results: Revenue: zł91.8m (down 3.4% from 1Q 2022). Net income: zł2.59m (down 47% from 1Q 2022). Profit margin: 2.8% (down from 5.2% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Annuncio • Jun 02
Selvita S.A., Annual General Meeting, Jun 27, 2023 Selvita S.A., Annual General Meeting, Jun 27, 2023, at 11:30 Central European Standard Time. Annuncio • Nov 23
Selvita S.A. has completed a Follow-on Equity Offering in the amount of PLN 78.7 million. Selvita S.A. has completed a Follow-on Equity Offering in the amount of PLN 78.7 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,000,000
Price\Range: PLN 78.7 Reported Earnings • Sep 17
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: zł103.4m (up 46% from 2Q 2021). Net income: zł3.80m (up zł4.10m from 2Q 2021). Profit margin: 3.7% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Annuncio • Jun 07
Selvita S.A., Annual General Meeting, Jun 30, 2022 Selvita S.A., Annual General Meeting, Jun 30, 2022, at 12:00 Central European Standard Time. Reported Earnings • Jun 02
First quarter 2022 earnings released First quarter 2022 results: Revenue: zł95.0m (up 35% from 1Q 2021). Net income: zł4.89m (down 48% from 1Q 2021). Profit margin: 5.2% (down from 13% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 22%, compared to a 13% growth forecast for the industry in Germany. Buying Opportunity • May 03
Now 23% undervalued Over the last 90 days, the stock is up 2.9%. The fair value is estimated to be €20.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 59% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings is also forecast to grow by 47% per annum over the same time period. Buying Opportunity • Apr 13
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 11%. The fair value is estimated to be €20.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 59% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings is also forecast to grow by 47% per annum over the same time period. Reported Earnings • Apr 05
Full year 2021 earnings released: EPS: zł0.81 (vs zł1.05 in FY 2020) Full year 2021 results: EPS: zł0.81 (down from zł1.05 in FY 2020). Revenue: zł315.7m (up 123% from FY 2020). Net income: zł14.9m (down 17% from FY 2020). Profit margin: 4.7% (down from 13% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 25%, compared to a 23% growth forecast for the pharmaceuticals industry in Germany. Buying Opportunity • Feb 15
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 3.3%. The fair value is estimated to be zł20.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 58% per annum over the last 3 years. Earnings per share has grown by 19% per annum over the last 3 years. Annuncio • Feb 02
Selvita Announces Management Changes Selvita informed about signing a preliminary contract to purchase another plot of land to expand its own laboratory space and secure further organic growth in Krakow, Poland. The integrated departments providing drug discovery services, operating in Krakow, Poznan, and Zagreb, will be led by Dr. Adrijana Vinter, who takes on a role of the Global Head of Drug Discovery and joins Selvita Management Board. Prior to that, for the past four years, Dr. Vinter has held the position of Managing Director at Fidelta. The Company intends to also integrate its business development and sales activities. Dr. Milosz Gruca, who will assume the position of Chief Commercial Officer, Executive Vice President, will be managing teams responsible for the development and sales of the integrated Selvita and Fidelta services offer in the area of drug discovery and development. Growing Group's scale of operations and its further development plans have led to creation of the Chief Operating Officer function, assumed by Dr. Miroslawa Zydron, the current Chemistry Department Director. Dr. Zydron will be responsible for the Group's operational activities, investments, and infrastructure management. Reported Earnings • Nov 25
Third quarter 2021 earnings: Revenues exceed analyst expectations Third quarter 2021 results: Revenue: zł81.5m (up 119% from 3Q 2020). Net loss: zł2.32m (down 153% from profit in 3Q 2020). Revenue exceeded analyst estimates by 1.9%. Over the next year, revenue is forecast to grow 30%, compared to a 32% growth forecast for the industry in Germany. Reported Earnings • Sep 23
Second quarter 2021 earnings released The company reported a mediocre second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: zł70.8m (up 94% from 2Q 2020). Net loss: zł302.7k (down 106% from profit in 2Q 2020). Reported Earnings • May 30
First quarter 2021 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: zł70.3m (up 128% from 1Q 2020). Net income: zł9.37m (up 175% from 1Q 2020). Profit margin: 13% (up from 11% in 1Q 2020). The increase in margin was driven by higher revenue. 
